COPA syndrome, 5 years after: Where are we?

Area of Science:

• Genetics
• Immunology
• Rheumatology

Background:

• COPA gene mutations cause a rare interferonopathy with variable clinical presentation.
• The condition often involves lung, joint, and kidney systems, with chronic diffuse alveolar hemorrhage being a common lung manifestation.
• High clinical non-penetrance and dominant inheritance necessitate careful family screening.

Purpose of the Study:

• To describe the clinical spectrum and genetic basis of COPA syndrome.
• To highlight the importance of recognizing COPA syndrome in patients with interferonopathies.
• To discuss current understanding of pathogenesis and emerging therapeutic strategies.

Main Methods:

• Literature review of COPA syndrome cases.
• Analysis of clinical and genetic data from affected individuals.
• Review of recent research on disease mechanisms and treatment.

Main Results:

• Heterozygous missense mutations in COPA are linked to interferonopathy.
• Lung involvement, particularly diffuse alveolar hemorrhage, is frequent and can lead to respiratory failure.
• Phenotype ranges from severe multi-organ disease to clinical non-penetrance, including isolated lupus nephritis.
• COPA mutations implicate STING-mediated interferon signaling in pathogenesis.

Conclusions:

• COPA syndrome requires thorough clinical evaluation, especially in cases of suspected interferonopathy or lupus nephritis.
• Family screening is recommended due to dominant inheritance and variable penetrance.
• JAK inhibitors show promise as a treatment, with further targeted therapies anticipated.